Metabolic reprogramming in head and neck cancer: therapeutic opportunities and challenges
Journal of Pharmacy and Pharmacology · 03.04.2026 · 78 (4)
DOI: 10.1093/jpp/rgag036 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 23.04.2026. Verfasst von Enas Bani-Ahmad und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Diagnostic and Therapeutic Sciences, Curtin University, Kent St, Bentley, WA 6102, Australia. Hauptthemen laut MEDLINE: Head and Neck Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
This review explores the metabolic pathways involved in the survival and apoptosis of head and neck cancer (HNC) cells, with a focus on how altered metabolism supports tumour growth and resistance to therapy.
Methods
Relevant literature was retrieved from Scopus using the keywords: ‘head and neck squamous cell carcinoma’, ‘glycolysis’, ‘the Warburg effect’, and ‘metabolism’. Articles published in English were included without time restrictions. Key findings Head and neck cancers (HNCs) exhibit dynamic and adaptable metabolic activity that supports proliferation and survival. Cancer cells often reprogramme their metabolism based on cell type, genetic alterations, and environmental conditions. A prominent feature is their reliance on glucose, demonstrated by elevated glucose uptake and increased glycolysis even under normoxic conditions—a phenomenon known as ‘the Warburg effect’. However, nutrient limitation may paradoxically promote tumour aggressiveness. Beyond glycolysis, evidence shows that HNC cells can exploit alternative metabolic pathways, such as lipid and amino acid metabolism, particularly when glucose becomes scarce. These metabolic adaptations present potential pharmaceutical targets for therapeutic intervention.
Conclusions
HNCs rely on flexible metabolic pathways to support growth and resist treatment. Their dependence on glucose and ability to shift to lipid and amino acid metabolism offer promising targets for therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Diagnostic and Therapeutic Sciences, Curtin University, Kent St, Bentley, WA 6102, Australia.
- Curtin Medical Research Institute, Curtin University, Kent St, Bentley, WA 6102, Australia.
- Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 3030, Jordan.
- Curtin Medical Research School, Curtin University, Kent St, Bentley, WA 6102, Australia.
- Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia.
- Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000, Thailand.
ORCID-Profile: Crispin R Dass
Zitieren
APA
Bani-Ahmad, E., Dass, J., & Dass, C. R. (2026). Metabolic reprogramming in head and neck cancer: therapeutic opportunities and challenges. Journal of Pharmacy and Pharmacology, 78(4). https://doi.org/10.1093/jpp/rgag036
Vancouver
Bani-Ahmad E, Dass J, Dass CR. Metabolic reprogramming in head and neck cancer: therapeutic opportunities and challenges. Journal of Pharmacy and Pharmacology. 2026;78(4). doi:10.1093/jpp/rgag036
BibTeX
@article{BaniAhmad2026,
author = {Bani-Ahmad, Enas and Dass, Joshua and Dass, Crispin R},
title = {Metabolic reprogramming in head and neck cancer: therapeutic opportunities and challenges},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
volume = {78},
number = {4},
doi = {10.1093/jpp/rgag036}
}
EUVIMED